3rd Annual MarketsandMarkets Next-Gen Immuno-Oncology Congress

3rd Annual MarketsandMarkets Next-Gen Immuno-Oncology Congress is organized by Markets and Markets (MnM) Conferences and will be held from Mar 14 - 15, 2019 at London, England, United Kingdom.

Conference Description:
Over the past several years, many immuno-oncology modalities have emerged. These modalities, which include checkpoint inhibition, adoptive T-cell therapy (ACT), and cancer vaccines, are often designed to evade immune responses. This is a rapidly growing therapeutic field that embraces the concept of modulating the immune system to recognize tumor cells and target them for destruction. Our Next Gen Immuno-Oncology Congress from past 2 years had gathered the professionals across the globe to deliver such latest developments.

Having completed two extremely successful editions, MarketsandMarkets' is coming up with “3rd Annual Next-Gen Immuno-Oncology Congress” gathering the academicians, researchers and scientists from research institutes pharmaceutical, biopharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Immune Checkpoint Inhibitors and Adoptive Cellular Therapy.

Key Highlights:
• Updates in development of monoclonal and Bispecific Ab’s
• Immune Checkpoint Inhibitors and Combinations
• Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
• Biomarkers and Cancer Vaccines
• CAR-T cell therapy, Adoptive Cell Therapy
• Tumor microenvironment
• Oncolytic Viruses

Who Should Attend:
Monoclonal and Bispecific Antibodies
• ADCs development Preclinical and Translational Oncology
• Oncology
• Bi-specifics- Preclinical and Translational
• Clinical development
• R&D- Discovery and process
• PKPD/ADME/Tox
• Antibody Engineering
• Antibody therapeutics
• Physio-Chemistry /Synthetic Chemistry and/ Bio conjugation
• Bioanalysis
 
Cell Therapy
• Oncology
• Clinical development
• R&D- discovery and process
• Discovery
• Target Validation
• Bioanalysis
• Therapeutic areas
• PKPD/ADME/Tox
• Biologics -antibody
• Cell-Based Immunotherapies
• Innate and adaptive immune cells
• Antibody engineering Tumour antigens and neoantigens

Immune Checkpoint Inhibitors
• Cancer immunotherapy
• Immune checkpoint targets
• Checkpoint inhibition
• Cellular therapy
• Clinical research
• Combination therapy
• Cancer Vaccines
• Preclinical and Translational Oncology R&D
• Immune biomarkers
• Immunology
• Cancer biology
• Immuno-oncology
• Tumour-associated mechanisms of immune suppression

Additional details will be posted as soon as they are available.